PMID- 35810217
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20220928
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 30
IP  - 10
DP  - 2022 Oct
TI  - Photobiomodulation: a promising innovative approach for preventing oral mucositis 
      in patients undergoing hematopoietic stem cell transplantation.
PG  - 8211-8216
LID - 10.1007/s00520-022-07280-3 [doi]
AB  - PURPOSE: This single-center retrospective study aims to assess the feasibility, 
      safety, and tolerability of CareMin650, a new photobiomodulation device, for both 
      preventing oral mucositis (OM) and reducing its severity in the setting of 
      hematopoietic stem cell transplantation (HCT). METHODS: Patients who underwent 
      autologous HCT for hematological malignancies between November 2020 and October 
      2021 could be included. Prophylactic photobiomodulation (PBM) was used daily from 
      day 1 of conditioning until the day of neutrophil recovery at a dose of 
      3 J/cm(2). Curative PBM was started at a dose of 6 J/cm(2) when at least one 
      grade 1 OM had occurred. For each OM case, time of onset, National Cancer 
      Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 grade 
      for OM, analgesic dose, and time to resolution were reported. RESULTS: 
      Twenty-five consecutive patients were included. The median age was 58 years 
      (range, 39-74) and 14 (56%) were male. Twenty-one patients (84%) received a 
      high-dose melphalan conditioning regimen for multiple myeloma, and 4 (16%) 
      patients received BEAM conditioning for aggressive lymphoma. A total of 178 
      CareMin650 sessions were performed, with a median of 7 days of application 
      (range, 4-12), with no device-related adverse events (AEs). According to the 
      NCI-CTCAE v5.0 scale, 76% (19 of 25) of patients presented grade 0 or 1 mucositis 
      (no ulcers), five patients (20%) developed small ulcers (grade 2), and only one 
      patient developed grade 4 mucositis. Satisfaction rates were high among patients 
      and users. CONCLUSION: Photobiomodulation provides excellent safety and 
      tolerance, as well as promising efficacy, both as a preventive and curative 
      strategy, in patients undergoing autologous HCT.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Stocker, Nicolas
AU  - Stocker N
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France. nicolas.stocker@aphp.fr.
AD  - Service Hematologie Clinique Et Therapie Cellulaire, Hopital Saint-Antoine, 
      AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. 
      nicolas.stocker@aphp.fr.
FAU - Baltes, Virginie
AU  - Baltes V
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
FAU - Bellaiche, Solal
AU  - Bellaiche S
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
FAU - Brouillard, Flora
AU  - Brouillard F
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
FAU - Belmoufid, Nadia
AU  - Belmoufid N
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
FAU - Rousseau, Celine
AU  - Rousseau C
AD  - Service Hematologie Clinique Et Therapie Cellulaire, Hopital Saint-Antoine, 
      AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.
FAU - Bonnin, Agnes
AU  - Bonnin A
AD  - Service Hematologie Clinique Et Therapie Cellulaire, Hopital Saint-Antoine, 
      AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.
FAU - Van de Wyngaert, Zoe
AU  - Van de Wyngaert Z
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
AD  - Service Hematologie Clinique Et Therapie Cellulaire, Hopital Saint-Antoine, 
      AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.
FAU - Ricard, Laure
AU  - Ricard L
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
AD  - Service Hematologie Clinique Et Therapie Cellulaire, Hopital Saint-Antoine, 
      AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.
FAU - Banet, Anne
AU  - Banet A
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
AD  - Service Hematologie Clinique Et Therapie Cellulaire, Hopital Saint-Antoine, 
      AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.
FAU - Malard, Florent
AU  - Malard F
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
AD  - Service Hematologie Clinique Et Therapie Cellulaire, Hopital Saint-Antoine, 
      AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.
FAU - Dulery, Remy
AU  - Dulery R
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
AD  - Service Hematologie Clinique Et Therapie Cellulaire, Hopital Saint-Antoine, 
      AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.
FAU - Mohty, Mohamad
AU  - Mohty M
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
AD  - Service Hematologie Clinique Et Therapie Cellulaire, Hopital Saint-Antoine, 
      AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.
FAU - Brissot, Eolia
AU  - Brissot E
AD  - Centre de Recherche Saint-Antoine (CRSA), INSERM, Sorbonne Universite, 75012, 
      Paris, France.
AD  - Service Hematologie Clinique Et Therapie Cellulaire, Hopital Saint-Antoine, 
      AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20220709
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Female
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Male
MH  - Melphalan/adverse effects
MH  - Middle Aged
MH  - *Mucositis/chemically induced
MH  - Retrospective Studies
MH  - *Stomatitis/etiology/pathology/prevention & control
MH  - Transplantation Conditioning/adverse effects
MH  - Transplantation, Autologous
OTO - NOTNLM
OT  - HCT
OT  - Hematological malignancies
OT  - Oral mucositis
OT  - Photobiomodulation
EDAT- 2022/07/10 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/07/09 23:19
PHST- 2022/05/19 00:00 [received]
PHST- 2022/07/06 00:00 [accepted]
PHST- 2022/07/10 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/07/09 23:19 [entrez]
AID - 10.1007/s00520-022-07280-3 [pii]
AID - 10.1007/s00520-022-07280-3 [doi]
PST - ppublish
SO  - Support Care Cancer. 2022 Oct;30(10):8211-8216. doi: 10.1007/s00520-022-07280-3. 
      Epub 2022 Jul 9.